Biotech Stocks


MannKind Corporation (MNKD) and BIOMM Advance Afrezza in Brazil

MannKind Corporation (NASDAQ:MNKD) and BIOMM announced the submission of a registration dossier to ANVISA, seeking the approval of Afrezza® (insulin human) inhalation powder …

Ladenburg Sees 35% Upside for Transenterix Inc (TRXC), RBC Gets More Cautious on Valeant Pharmaceuticals Intl Inc (VRX)

Healthcare analysts take different approaches to valuing Transenterix and Valeant.

Uniqure NV (QURE) Is Getting the Street All Fired Up on Its Gene Therapy Candidate in Hemophilia B; Oppenheimer Spotlights Efficacy/Safety Strength

Hartaj Singh believes QURE trots out an upper hand advantage with AMT-061.

DURECT Corporation (DRRX) Shares Collapse – Here’s Why

Friday turned out to be a nightmare for DURECT Corporation (NASDAQ:DRRX) investors, after the drug maker announced that its pain relief candidate Posimir failed …

Aurinia Pharmaceuticals Inc (AUPH) Announces Clinical Development for New Indications

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are rising nearly 4% in pre-market trading Friday, after the drug maker announced plans to expand its voclosoprin renal …

Analysts Chime in on Celgene Corporation (CELG) Crohn’s Dud and Gilead Sciences, Inc. (GILD) Winning FDA Nod for Yescarta

Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.

Omeros Corporation (OMER) Case Report Presented at EBMT Annual Meeting

Omeros Corporation (NASDAQ:OMER) announced the presentation of a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and …

Cantor Sheds Light on Teva Pharmaceutical Industries Ltd (ADR) (TEVA) as Novartis (NVS) Facing the Generics Pricing Heat

Louise Chen anticipates more generic pricing pressure hit 3Q earnings for generic manufacturers.

Cowen Shines Light on Uniqure NV (QURE) as the Latter Advances Padua Variant AMT-061 into Phase 3

Uniqure NV is back in the race for a hemophilia B gene therapy.

‘Stock Market Wizard’ Michael Masters Puts His Money on Transenterix Inc (TRXC), Says Bye Bye to Gilead Sciences, Inc. (GILD)

Did this $4 billion fund make the right call on these two soaring biotechs?

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts